Top

Published in:

01-12-2010 | Original Article

The importance of anti-insulin antibody in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or multiple daily insulin injections therapy

Authors: S. B. Sahin, S. Cetinkalp, A. G. Ozgen, F. Saygili, C. Yilmaz

Published in: Acta Diabetologica | Issue 4/2010

Abstract

To investigate the influence of two insulin administration modalities, continuous subcutaneous insulin infusion (CSII) and multiple daily insulin injections (MDI) therapy with insulin analogues, on the development of insulin antibodies (IAs) in patients with type 1 diabetes mellitus and to assess the impact of IAs on glucose control and hypoglycaemia. 96 patients with type 1 diabetes mellitus treated with CSII (n = 48) or MDI (n = 48) were included in the study. Age, duration of diabetes, A1c, preprandial and postprandial blood glucose and hypoglycaemic events were compared between IA positive and negative patients. IA levels were higher in the CSII group (% 24.6 ± 14.2) than the MDI group (% 13.2 ± 9.9). Duration of diabetes and age were not associated with IA positiveness. While A1c, preprandial blood glucose and the frequency of hypoglycaemic events were similar in two groups, postprandial blood glucose was lower in IA positive group (P = 0.03). Patients with type 1 diabetes mellitus treated with CSII with insulin analogues had higher IA levels when compared to MDI therapy. However, the development of IAs did not impair the glycaemic control.

Van Haeften TW (1989) Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care 12(9):641–648 (Review)CrossRefPubMed

Kurtz AB, Nabarro JD (1980) Circulating insulin-binding antibodies. Diabetologia 19(4):329–334 (Review)CrossRefPubMed

Oak S, Phan TH, Gilliam LK, Hirsch IB, Hampe CS (2010) Animal insulin therapy induces a biased insulin antibody response that persists for years after introduction of human insulin. Acta Diabetol 47(2):131–135CrossRefPubMed

Brange J, Owens DR, Kang S, Vølund A (1990) Monomeric insulins and their experimental and clinical implications. Diabetes Care 13(9):923–954CrossRefPubMed

Ottesen JL, Nilsson P, Jami J, Weilguny D, Dührkop M, Bucchini D et al (1994) The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37(12):1178–1185CrossRefPubMed

Jaeger C, Winter S, Eckhard M, Hardt P, Brendel MD, Bretzel RG (2008) Binding characteristics and crossreactivity of insulin autoantibodies and insulin antibodies directed to three different insulin molecules. Acta Diabetol 45(3):191–194CrossRefPubMed

Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR et al (2008) Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 51(6):941–951 (Review)CrossRefPubMed

Pickup JC, Sutton AJ (2008) Severe hypoglycaemia and glycaemic control in type 1 diabetes:meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 25(7):765–774 (Review)CrossRefPubMed

Dahl-Jørgensen K, Torjesen P, Hanssen KF, Sandvik L, Aagenaes O (1987) Increase in insulin antibodies during continuous subcutaneous insulin infusion and multiple-injection therapy in contrast to conventional treatment. Diabetes 36(1):1–5CrossRefPubMed

10.

Colquitt J, Royle P, Waugh N (2003) Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med (10):863–866 (Review)

11.

Radermecker RP, Scheen AJ (2004) Continuous subcutaneous insulin infusion with shortacting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 20(3):178–188 (Review)CrossRefPubMed

12.

Moisés RS, Sá JR, Chacra AR, Russo EM (1990) Relationship between insulin antibodies and metabolic control in type I diabetes mellitus. Braz J Med Biol Res 23(12):1243–1252PubMed

13.

Livneh A, Avraham H, Bistritzer T, Weisglass L, Theodor R, Sack J (1990) Deleterious effect of anti-insulin antibodies on diabetes control. Isr J Med Sci 26(1):11–15PubMed

14.

Fernández Castañer M, Pérez M, Maravall J, Montaña E, Soler J (1996) Lack of relationship between insulin antibodies, metabolic control and insulin requirements in type 1 diabetes. Diabet Med 13(7):686–687CrossRefPubMed

15.

Wredling R, Lins PE, Adamson U (1990) Prevalence of anti-insulin antibodies and its relation to severe hypoglycaemia in insulin-treated diabetic patients. Scand J Clin Lab Invest 50(5):551–557CrossRefPubMed

16.

Dozio N, Beretta A, Castiglioni M, Rosa S, Scavini M, Belloni C et al (1996) Insulin antibodies do not preclude optimization of metabolic control in women with IDDM during pregnancy. Diabetes Care 19(9):979–982CrossRefPubMed

17.

Sakata S, Matsuda M, Komaki T, Miura K (1986) Effect of anti-insulin antibodies on glycemic control in insulin treated diabetic patients. Immunol Invest 15(8):791–799CrossRefPubMed

18.

Antony G, Cooper SG, Svejkar LC (1991) Continuous subcutaneous insulin infusion (CSII) and insulin antibodies in rabbits. Diabetes Res Clin Pract 12(1):41–51CrossRefPubMed

19.

de Beaufort CE, Houtzagers CM, Bruining GJ, Aarsen RS, den Boer NC, Grose WF et al (1989) Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: two-year follow-up of a randomized, prospective trial. Diabet Med 6(9):766–771CrossRefPubMed

20.

Beck-Nielsen H, Richelsen B, Hasling C, Nielsen OH, Heding L, Sørensen NS (1984) Improved in vivo insulin effect during continuous subcutaneous insulin infusion in patients with IDDM. Diabetes 33(9):832–837CrossRefPubMed

21.

Beck-Nielsen H, Richelsen B, Schwartz Sørensen N, Hother Nielsen O (1985) Insulin pump treatment: effect on glucose homeostasis, metabolites, hormones, insulin antibodies and quality of life. Diabetes Res 2(1):37–43PubMed

22.

Henrivaux P, Daubresse JC, Scheen A, Luyckx A, Lefèbvre PJ (1985) Effect of long- term continuous subcutaneous insulin infusion (CSII) on serum anti- insulin antibodies: comparison between pocine and semisynthetic human insulin. Diabetes Res Clin Pract (Suppl 1): S234–S235

23.

Scheen AJ, Henrivaux P, Jandrain B, Lefebvre PJ (1986) Anti-insulin antibodies and metabolic deterioration after interruption of continuous subcutaneous insulin infusion. Diabetes Care 9(6):673–674PubMed

24.

Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS (2007) Immunological responses to exogenous insulin. Endocr Rev 28(6):625–652 (Epub 2007 Sep 4 Review)

25.

Chawla AS, Hinberg I, Blais P, Johnson D (1985) Aggregation of insulin, containing surfactants, in contact with different materials. Diabetes 34(5):420–424CrossRefPubMed

26.

Robbins DC, Cooper SM, Fineberg SE, Mead PM (1987) Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients. Diabetes 36(7):838–841CrossRefPubMed

27.

Miller RA (1996) The aging immune system: primer and prospectus. Science 273(5271):70–74 (Review)CrossRefPubMed

28.

Fineberg SE, Galloway JA, Fineberg NS, Goldman J (1983) Effects of species of origin, purification levels, and formulation on insulin immunogenicity. Diabetes 32(7):592–599CrossRefPubMed

29.

Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A (2005) Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 90(6):3287–3294CrossRefPubMed

30.

Francis AJ, Hanning I, Alberti KG (1985) The influence of insulin antibody levels on the plasma profiles and action of subcutaneously injected human and bovine short acting insulins. Diabetologia 28(6):330–334CrossRefPubMed

31.

Van Haeften TW, Heiling VJ, Gerich JE (1987) Adverse effects of insulin antibodies on postprandial plasma glucose and insulin profiles in diabetic patients without immune insulin resistance. Implications for intensive insulin regimens. Diabetes 36(3):305–309CrossRefPubMed

32.

Bistritzer T, Sack J, Theodor R, Weissglass L, Ben-Bassat I, Lahav M (1984) Correlation between HbA1c, purified insulins, diabetic control, and insulin antibodies in diabetic children. Horm Res 20(3):178–185CrossRefPubMed

33.

Goswami R, Jaleel A, Kochupillai NP (2000) Insulin antibody response to bovine insulin therapy: functional significance among insulin requiring young diabetics in India. Diabetes Res Clin Pract 49(1):7–15CrossRefPubMed

34.

Gonen B, Goldman J, Baldwin D, Goldberg RB, Ryan WG, Blix PM et al (1979) Metabolic control in diabetic patients. Effect of insulin-secretory reserve (measured by plasma C-peptide levels) and circulating insulin antibodies. Diabetes 28(8):749–753CrossRefPubMed

35.

Hübinger A, Becker A, Gries FA (1988) Total insulin levels in type 1 diabetic patients with insulin antibodies and their effect on insulin requirement and metabolic control. Diabetes Res 7(2):65–69PubMed

36.

Kabadi UM, Birkenholz M (1992) Metabolic control following transfer from mixed bovine-porcine insulin to human insulin in subjects with IDDM: influence of the presence of insulin antibodies. Diabetes Res 19(4):187–193PubMed

37.

Virgili F, Frigato F, Magnanini PG, Coronel GA, Iavicoli M (1988) Reduction in insulin antibodies 42 months after transfer from porcine to human monocomponent insulins. Diabetes Res 9(1):19–20PubMed

38.

Walford S, Allison SP, Reeves WG (1982) The effect of insulin antibodies on insulin dose and diabetic control. Diabetologia 22(2):106–110CrossRefPubMed

39.

Asplin CM, Hartog M, Goldie DJ, Alberti KG, Smythe P, Binder C et al (1978) A comparison between diabetics receiving a high or low daily insulin dosage. Horm Metab Res 10(5):365–369CrossRefPubMed

40.

Kerp L, Kasemir H (1976) High and low affinity insulin antibodies. Acta Endocrinol Suppl (Copenh) 205:211–222

41.

Keilacker H, Rjasanowski I, Ziegler M, Michaelis D, Woltanski KP, Besch W (1982) Insulin antibodies in juvenile diabetes mellitus. Correlations to diabetic stability, insulin requirement and duration of insulin treatment. Horm Metab Res 14(5):227–232CrossRefPubMed

42.

Kim MR, Sheeler LR, Mansharamani N, Haug MT, Faiman C, Gupta MK (1997) Insulin antibodies and hypoglycemia in diabetic patients. Can a quantitative analysis of antibody binding predict the risk of hypoglycemia? Endocrine 6(3):285–291CrossRefPubMed

43.

Radermecker RP, Renard E, Scheen AJ (2009) Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control. Diabetes Metab Res Rev 25(6):491–501CrossRefPubMed

44.

Koyama R, Nakanishi K, Kato M, Yamashita S, Kuwahara H, Katori H (2005) Hypoglycemia and hyperglycemia due to insulin antibodies against therapeutic human insulin: treatment with double filtration plasmapheresis and prednisolone. Am J Med Sci 329(5):259–264CrossRefPubMed

45.

Matsuyoshi A, Shimoda S, Tsuruzoe K, Taketa K, Chirioka T, Sakamoto F et al (2006) A case of slowly progressive type 1 diabetes with unstable glycemic control caused by unusual insulin antibody and successfully treated with steroid therapy. Diabetes Res Clin Pract 72(3):238–243CrossRefPubMed

46.

Suzuki K, Hirayama S, Ito S (1997) A case of a non-insulin dependent diabetic patient with regular spontaneous hypoglycemic attacks, which were due to insulin-binding antibodies induced by human insulin therapy. Tohoku J Exp Med 182(2):163–173CrossRefPubMed

47.

Asplin CM, Hartog M, Goldie DJ (1978) The relationship between circulating free and bound insulin, insulin antibodies, insulin dosage and diabetic control in insulin treated diabetics. Acta Endocrinol (Copenh) 87(2):330–338

Title: The importance of anti-insulin antibody in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or multiple daily insulin injections therapy
Authors: S. B. Sahin
S. Cetinkalp
A. G. Ozgen
F. Saygili
C. Yilmaz
Publication date: 01-12-2010
Publisher: Springer Milan
Published in: Acta Diabetologica / Issue 4/2010
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-010-0221-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The importance of anti-insulin antibody in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or multiple daily insulin injections therapy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Fatty acids inhibit insulin-mediated glucose transport associated with actin remodeling in rat L6 muscle cells

Body mass index is more strongly associated with hypertension than waist circumference in apparently healthy Japanese men and women

STZ-induced skeletal muscle atrophy is associated with increased p65 content and downregulation of insulin pathway without NF-κB canonical cascade activation

Encephalopathies: the emerging diabetic complications

Insulin and its analogs: actions via insulin and IGF receptors

Joint and distinct risk factors associated with micro- and macrovascular complications in a cohort of type 2 diabetic patients cared through disease management

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page